KeyMed Biosciences Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Public

  • Employees
  • 1,768

Employees

  • Stock Symbol
  • 02162

Stock Symbol

  • Investments
  • 3

  • Share Price
  • $8.90
  • (As of Friday Closing)

KeyMed Biosciences General Information

Description

Keymed Biosciences Inc is a biotechnology company with multiple clinical-stage assets. The company is focused on the in-house discovery and development of biological therapies that address large underserved medical needs in the autoimmune and oncology therapeutic areas. Its clinical-stage drug candidates include CM310, CM326, CM313, and CM336 among others. The company is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment. Geographically, it generates a majority of its revenue from overseas markets and the rest from Mainland China.

Contact Information

Formerly Known As
2Health Biosciences Inc.
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Building D2, Chengdu Tianfu International Bio-town
  • Shuangliu District
  • Chengdu, Sichuan
  • China
+86 028
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
HKG
Vertical(s)
Corporate Office
  • Building D2, Chengdu Tianfu International Bio-town
  • Shuangliu District
  • Chengdu, Sichuan
  • China
+86 028

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

KeyMed Biosciences Stock Performance

As of 13-Nov-2026, KeyMed Biosciences’s stock price is $8.90. Its current market cap is $2.62B with 295M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$8.90 $9.05 $5.72 - $11.44 $2.62B 295M 2.18M $0.38

KeyMed Biosciences Financials Summary

As of 30-Jun-2026, KeyMed Biosciences has a trailing 12-month revenue of $119M.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 2,497,307 1,739,851 854,872 1,372,903
Revenue 119,278 99,608 59,665 50,050
EBITDA 159,646 (66,187) (67,632) (50,618)
Net Income 110,563 (72,677) (71,806) (50,793)
Total Assets 834,455 602,789 515,961 547,770
Total Debt 102,541 112,702 103,182 59,068
Public Fundamental Data provided by Morningstar, Inc. disclaimer

KeyMed Biosciences Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore KeyMed Biosciences‘s full profile, request access.

Request a free trial

KeyMed Biosciences Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore KeyMed Biosciences‘s full profile, request access.

Request a free trial

KeyMed Biosciences Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

KeyMed Biosciences Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore KeyMed Biosciences‘s full profile, request access.

Request a free trial

KeyMed Biosciences Investments (3)

KeyMed Biosciences’s most recent deal was a Secondary Transaction - Private with Chengdu Kangnuoxing for . The deal was made on 26-Jun-2023.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Chengdu Kangnuoxing 26-Jun-2023 Secondary Transaction - Private Biotechnology
Tiannuojiancheng Pharma (InnoCare Pharma / Keymed Biosciences) 17-Sep-2021 Joint Venture Drug Discovery
KYM Biosciences 02-Dec-2019 Joint Venture Drug Discovery
To view KeyMed Biosciences’s complete investments history, request access »

KeyMed Biosciences ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

36.14 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view KeyMed Biosciences’s complete esg history, request access »

KeyMed Biosciences Exits (1)

KeyMed Biosciences’s most recent exit was on 26-Jun-2023 from Chengdu Kangnuoxing. The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
Chengdu Kangnuoxing 26-Jun-2023 Completed
To view KeyMed Biosciences’s complete exits history, request access »

KeyMed Biosciences FAQs

  • When was KeyMed Biosciences founded?

    KeyMed Biosciences was founded in 2016.

  • Where is KeyMed Biosciences headquartered?

    KeyMed Biosciences is headquartered in Chengdu, China.

  • What is the size of KeyMed Biosciences?

    KeyMed Biosciences has 1,768 total employees.

  • What industry is KeyMed Biosciences in?

    KeyMed Biosciences’s primary industry is Drug Discovery.

  • Is KeyMed Biosciences a private or public company?

    KeyMed Biosciences is a Public company.

  • What is KeyMed Biosciences’s stock symbol?

    The ticker symbol for KeyMed Biosciences is 02162.

  • What is the current stock price of KeyMed Biosciences?

    As of 13-Nov-2026 the stock price of KeyMed Biosciences is $8.90.

  • What is the current market cap of KeyMed Biosciences?

    The current market capitalization of KeyMed Biosciences is $2.62B.

  • What is KeyMed Biosciences’s current revenue?

    The trailing twelve month revenue for KeyMed Biosciences is $119M.

  • What is KeyMed Biosciences’s annual earnings per share (EPS)?

    KeyMed Biosciences’s EPS for 12 months was $0.38.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process